Anteris Technologies ( (AU:AVR) ) has provided an update.
Anteris Technologies reported its 2024 financial results and provided a corporate update, highlighting a successful U.S. IPO on Nasdaq and preparations for the DurAVR® THV’s pivotal trial. The company achieved significant milestones including the submission of an IDE to the FDA, positive patient data, and the first cases of the European Early Feasibility Study. Anteris also expanded manufacturing capabilities and increased awareness of its DurAVR® THV system through presentations at major medical conferences, positioning itself for future growth and impact in the structural heart market.
More about Anteris Technologies
Anteris Technologies Global Corp. is a global structural heart company focused on designing, developing, and commercializing advanced medical devices to restore healthy heart function. The company operates in the medical device industry, with a primary focus on structural heart solutions, particularly the DurAVR® Transcatheter Heart Valve (THV) system.
Average Trading Volume: 3,501
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $175.7M
For a thorough assessment of AVR stock, go to TipRanks’ Stock Analysis page.